Skip to main content

Advertisement

SpringerLink
Log in

Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  PubMed  Google Scholar 

  2. Druker BJ, Tamura S, Buchdunger E, Ohno-Jones S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of bcr/abl positive cells. Nat Med 1996; 2: 561–566.

    Article  CAS  Google Scholar 

  3. Hochhaus A, Kreil S, Corbin A, La Rosee P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.

    Article  CAS  Google Scholar 

  4. Koh LP, Hwang WY, Chuah CT, Linn YC, Goh YT, Tan CH et al. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. Bone Marrow Transplant 2003; 31: 305–308.

    Article  CAS  Google Scholar 

  5. Lee S, Kim DW, Kim YJ, Chung NG, Kim YL, Hwang JY et al. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2003; 102: 3068–3070.

    Article  CAS  Google Scholar 

  6. Kantarjian HM, O'Brien S, Cortes JE, Giralt S, Rios MB, Shan J et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.

    CAS  Google Scholar 

  7. Kim YJ, Kim DW, Lee S, Chung NG, Hwang JY, Kim YL et al. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial. Bone Marrow Transplant 2004; 33: 535–542.

    Article  CAS  Google Scholar 

  8. Visani G, Rosti G, Bandini G, Tosi P, Isidori A, Malagola M et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukemia. Br J Haematol 2000; 109: 722–728.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (01-PJ10-PG6-01GN16-0005).

Author information

Authors and Affiliations

  1. Molecular Hematology Laboratory,Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea, Seoul, Korea

    D-W Kim, Y-J Chung, S Lee, Y-J Kim, N-G Chung, J A Kim, I-H Oh, T-G Kim, Y-L Kim, H-G Goh, S-H Kim, B Cho, H-J Kim, C-K Min, J W Lee, J Y Jin, C-W Han, J W Kim, W-S Min, H-K Kim, C-C Kim & H J Kim

  2. Genome Research Center for Hematopoietic diseases, Chonnam National University Hospital, Kwangju, Korea

    H J Kim

Authors
  1. D-W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y-J Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N-G Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J A Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I-H Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T-G Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y-L Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H-G Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S-H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C-K Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J Y Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C-W Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. J W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. W-S Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. H-K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. C-C Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. H J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, DW., Chung, YJ., Lee, S. et al. Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 18, 1907–1909 (2004). https://doi.org/10.1038/sj.leu.2403502

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403502

  • Springer Nature Limited

This article is cited by

Search

Navigation